tradingkey.logo
搜尋

Bone Biologics Corp

BBLG
添加自選
0.850USD
-0.010-1.17%
收盤 07-31 16:00美東報價延遲15分鐘
1.53M總市值
虧損本益比TTM

關於 Bone Biologics Corp 公司

Bone Biologics Corporation is a clinical-stage developer of orthobiologic products for spine fusion markets. The Company is focused on bone regeneration in lumbar spinal fusion using neural epidermal growth factor-like 1 protein (NELL-1) in combination with demineralized bone matrix (DBM), a demineralized bone matrix from the Musculoskeletal Transplant Foundation (MTF) Biologics. The combination NELL-1/DBM medical device is an osteopromotive recombinant protein that provides target specific control over bone regeneration. NELL-1 in combination with DBM. NELL-1, a proprietary skeletal-specific growth factor that is a bone void filler. NELL-1 provides regulation over skeletal tissue formation and stem cell differentiation during bone regeneration. The DBM Demineralized Bone Putty provided as part of the convenience kit with NELL-1/DBM is a Class II device. DBM Putty is a matrix composed of processed human cortical bone.

Bone Biologics Corp簡介

公司代碼BBLG
公司名稱Bone Biologics Corp
上市日期Nov 27, 2015
CEOFrelick (Jeffrey)
員工數量2
證券類型Ordinary Share
年結日Nov 27
公司地址2 Burlington Woods Dr Ste 100
城市BURLINGTON
上市交易所NASDAQ OMX - NASDAQ BASIC
國家United States of America
郵編01803-4551
電話17815524452
網址https://www.bonebiologics.com/
公司代碼BBLG
上市日期Nov 27, 2015
CEOFrelick (Jeffrey)

Bone Biologics Corp公司高管

名稱
名稱/職務
職務
持股
持股變動
Mr. Jeffrey Frelick
Mr. Jeffrey Frelick
President, Chief Executive Officer
President, Chief Executive Officer
360.00
+0.28%
Ms. Deina H. Walsh, CPA
Ms. Deina H. Walsh, CPA
Chief Financial Officer
Chief Financial Officer
313.00
--
Mr. Bruce Stroever
Mr. Bruce Stroever
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Siddhesh Rajendra (Sid) Angle, Ph.D.
Dr. Siddhesh Rajendra (Sid) Angle, Ph.D.
Independent Director
Independent Director
--
--
Mr. Robert E. (Rob) Gagnon
Mr. Robert E. (Rob) Gagnon
Independent Director
Independent Director
--
--
Mr. Phillip T. Meikle
Mr. Phillip T. Meikle
Independent Director
Independent Director
--
--
Mr. Jody Cain
Mr. Jody Cain
Investor Relation
Investor Relation
--
--
名稱
名稱/職務
職務
持股
持股變動
Mr. Jeffrey Frelick
Mr. Jeffrey Frelick
President, Chief Executive Officer
President, Chief Executive Officer
360.00
+0.28%
Ms. Deina H. Walsh, CPA
Ms. Deina H. Walsh, CPA
Chief Financial Officer
Chief Financial Officer
313.00
--
Mr. Bruce Stroever
Mr. Bruce Stroever
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Siddhesh Rajendra (Sid) Angle, Ph.D.
Dr. Siddhesh Rajendra (Sid) Angle, Ph.D.
Independent Director
Independent Director
--
--
Mr. Robert E. (Rob) Gagnon
Mr. Robert E. (Rob) Gagnon
Independent Director
Independent Director
--
--
Mr. Phillip T. Meikle
Mr. Phillip T. Meikle
Independent Director
Independent Director
--
--

常見問題

Bone Biologics Corp的前五大股東是誰?

Bone Biologics Corp的前五大股東如下:Mr. Jeffrey Frelick

有多少機構持有Bone Biologics Corp(BBLG)的股份?

截至2026Q1,共有17家機構持有Bone Biologics Corp的股份,合計持有的股份價值約為58.41K,占公司總股份的3.25% 。與2025Q4相比,機構持股有所增加,增幅為22009.00。
tradingkey.logo
風險提示:我們的網站和行動應用程式僅提供關於某些投資產品的一般資訊。Finsights 不提供財務建議或對任何投資產品的推薦,且提供此類資訊不應被解釋為 Finsights 提供財務建議或推薦。
投資產品存在重大投資風險,包括可能損失投資的本金,且可能並不適合所有人。投資產品的過去表現並不代表其未來表現。
Finsights 可能允許第三方廣告商或關聯公司在我們的網站或行動應用程式的任何部分放置或投放廣告,並可能根據您與廣告的互動情況獲得報酬。
© 版權所有: FINSIGHTS MEDIA PTE. LTD. 版權所有